NCT02208024已完成不适用
Phase I Study to Evaluate the Feasibility of Neoadjuvant Stereotactic Body Radiation Therapy for Resectable Adenocarcinoma of the Pancreatic Head and/or Body
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 18
- 试验地点
- 2
- 主要终点
- Number of Participants With Acute (Within 3 Months of Treatment) Grade 3 or Greater Gastrointestinal Toxicity
研究概览
简要总结
The purpose of this study is to test the safety of focused radiation (Stereotactic Body Radiation Therapy, SBRT) on patients with pancreatic cancer that will be removed surgically.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 19 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age >18 years.
- •Histologically confirmed pancreatic adenocarcinoma of the head and/or body; at least the majority of the histopathologic specimen must be identified as adenocarcinoma.
- •Pancreatic tumors must be considered resectable at time of treatment planning. Definition of resectable: no metastases, less than 180 degree involvement of superior mesenteric vein or portal vein, no involvement of hepatic artery, superior mesenteric artery or celiac artery
- •No active infection requiring hospitalization
- •Adequate labs
- •Life expectancy > 3 months.
- •Patient is to have received chemotherapy prior to enrollment. This will typically consist of 3-4 cycles of chemotherapy. Patients will have a 2 week break between last chemotherapy administration and start of SBRT.
排除标准
- •Presence of metastatic disease.
- •Infections requiring systemic antibiotic treatment.
结局指标
主要结局
Number of Participants With Acute (Within 3 Months of Treatment) Grade 3 or Greater Gastrointestinal Toxicity
时间窗: 3 months
AEs were reviewed for gastrointestinal toxicity. Toxicities of note include grade 3 or greater gastritis, enteritis, fistula, or ulcer and any other grade 3 or greater gastrointestinal toxicity.
次要结局
- Number of Participants With Late (Greater Than 3 Months After Treatment) Grade 2 Gastritis, Enteritis, Fistula, and Ulcer or Any Other Grade 3 or Greater Gastrointestinal Toxicity(1 year)
- Metastasis Free Survival(1 year)
- Overall Survival(1 year)
- Local Progression Free Survival(1 year)
研究者
Jordan Kharofa
Assistant Professor Radiation Oncology
University of Cincinnati
研究点 (2)
Loading locations...
相似试验
Unknown
1 期
Stereotactic Body Radiation Therapy Combined With Anti-PD-1 Antibody in Metastatic Triple Negative Breast CancerMetastatic Breast CancerNCT03151447Fudan University18
已完成
1 期
Trial of Stereotactic Body Radiotherapy With Concurrent Pembrolizumab in Metastatic Urothelial CancerMetastatic Urothelial CancerNCT02826564University Hospital, Ghent18
已完成
不适用
Safety and Preliminary Efficacy of SBRT in Patients With Metastatic RCC Treated With Targeted or IO TherapyMetastatic Renal Cell CarcinomaNCT02864615Kidney Cancer Research Bureau17
进行中（未招募）
早期 1 期
SBRT + Atezolizumab + Bevacizumab in Resectable HCCResectable Hepatocellular CarcinomaHepatocellular CarcinomaNCT04857684Massachusetts General Hospital20
已完成
1 期
SBRT Pre-operatively for Pancreatic CancerPancreatic NeoplasmsNCT02308722University of Oxford12